Company profile
WEED, Inc.
OTC: BUDZ · Healthcare · Drug Manufacturers - Specialty & Generic
#1161 of 1,418 Healthcare companies by revenue
EA Score
19DFH 12DQ 25GM —SS 37
v0.1 · 55/100 weight · provisional
↑ listing tenure, market scale · ↓ Piotroski F, workforce scale
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$1.4M
Employees
2
as of 2026-08-24
Market cap
$4.4M
as of 2026-08-24
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$1.4M-$1.4M2025
Operating income-$1.3M-$1.3M2025
Total assets$559.9k$559.9k2025
Liabilities$1.2M$1.2M2025
Equity-$688.4k-$688.4k2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY18
FY19
FY20
FY23
FY23
FY25
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is WEED, Inc.’s revenue?
WEED, Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Processa Pharmaceuticals, Inc.39DPharmaCyte Biotech, Inc.——ENDRA Life Sciences Inc.25DMustang Bio, Inc.41DStimcell Energetics, Inc.20DPharmaTher Holdings Ltd.——Neighbors
Pima →Key facts
CEOGlenn E. Martin
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersTucson, AZ
ExchangeOTC: BUDZ
Employees2
IPO date2010-04-05
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.